Deerfield Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Deerfield Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-313,000	Closed	-$25M	–	141
2022 Q2	$25M	Sell	313,000 -152,000	-33%	-$14.4M	0.51%	52
2022 Q1	$48.9M	Buy	+465,000	New	+$45.3M	1.09%	28
2020 Q4	–	Sell	-1,832,767	Closed	-$142M	–	150
2020 Q3	$142M	Sell	1,832,767 -118,444	-6%	-$8.15M	3.47%	5
2020 Q2	$108M	Sell	1,951,211 -3,937,300	-67%	-$168M	3.16%	6
2020 Q1	$174M	Buy	5,888,511 +1,146,200	+24%	+$38.8M	5.54%	3
2019 Q4	$172M	Sell	4,742,311 -1,720,323	-27%	-$52.7M	5.48%	3
2019 Q3	$176M	Hold	6,462,634	–	–	7.17%	1
2019 Q2	$155M	Hold	6,462,634	–	–	5.59%	1
2019 Q1	$171M	Sell	6,462,634 -363,085	-5%	-$8.6M	6.55%	1
2018 Q4	$133M	Buy	6,825,719 +215,825	+3%	+$4.23M	5.34%	1
2018 Q3	$129M	Hold	6,609,894	–	–	4.64%	1
2018 Q2	$109M	Hold	6,609,894	–	–	3.84%	2
2018 Q1	$93.9M	Buy	6,609,894 +268,000	+4%	+$3.96M	3.25%	4
2017 Q4	$92.6M	Sell	6,341,894 -575,176	-8%	-$8.08M	3.64%	3
2017 Q3	$87.7M	Sell	6,917,070 -2,081,343	-23%	-$26.5M	3.95%	4
2017 Q2	$107M	Sell	8,998,413 -1,946,575	-18%	-$24.2M	5.7%	2
2017 Q1	$162M	Buy	10,944,988 +1,988,000	+22%	+$32.2M	6.24%	2
2016 Q4	$145M	Buy	8,956,988 +2,522,549	+39%	+$45.7M	5.96%	1
2016 Q3	$117M	Sell	6,434,439 -7,305,822	-53%	-$143M	5.43%	3
2016 Q2	$226M	Hold	13,740,261	–	–	8.89%	1
2016 Q1	$228M	Buy	13,740,261 +2,055,460	+18%	+$36M	9.69%	1
2015 Q4	$253M	Buy	11,684,801 +3,603,394	+45%	+$70.1M	10.26%	1
2015 Q3	$160M	Sell	8,081,407 -4,178,468	-34%	-$132M	6.2%	1
2015 Q2	$426M	Sell	12,259,875 -532,814	-4%	-$16.3M	14.19%	1
2015 Q1	$332M	Buy	12,792,689 +1,093,642	+9%	+$20M	10.76%	2
2014 Q4	$151M	Buy	11,699,047 +6,178,481	+112%	+$77.3M	5.42%	3
2014 Q3	$67.8M	Buy	5,520,566 +4,907,779	+801%	+$57M	2.47%	7
2014 Q2	$9.69M	Sell	612,787 -698,143	-53%	-$9.96M	0.39%	66
2014 Q1	$19.8M	Sell	1,310,930 -3,327,958	-72%	-$37.6M	0.81%	42
2013 Q4	$35.3M	Buy	+4,638,888	New	+$25M	1.83%	16

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Deerfield Management's HZNP Position: Q3 2022 in Review

Deerfield Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 313,000 shares — an estimated $25M sold.

Deerfield Management first reported a position in HZNP in Q4 2013 and held it in 30 quarters. The position peaked at $426M in Q2 2015. 530 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

Deerfield Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
Deerfield Management sold 313,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $25M.
Deerfield Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2013 and held it in 30 quarters.
Deerfield Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $426M in Q2 2015.
530 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Deerfield Management's 13F filing for Q3 2022, filed 14 Nov 2022.